Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

G. Schwartz, Gregory; Gabríel Steg, Philippe; Szarek, Michael; L. Bhatt, Deepak; Bittner, Vera; Díaz, Rafael; M. Edelberg, Jay; G. Goodman, Shaun; Hanotin, Corinne; A. Harrington, Robert; Wouter Jukema, J.; Lecorps, Guillaume; W. Mahaffey, Kenneth; Moryusef, Angèle; Pordy, Robert; Quintero, Kirby; T. Roe, Matthew; J. Sasiela, William; Tamby, Jean‐François; Tricoci, Pierluigi; D. White, Harvey; M. Zeiher, Andreas

doi:10.1056/nejmoa1801174

Public

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Published in New England Journal of Medicine • Nov 7, 2018

Authors:

Gregory G. Schwartz

Philippe Gabríel Steg

Michael Szarek

Abstract

BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an ...

Subject

Alirocumab

Acute coronary syndrome

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!